Ignite Planners LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 1.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,948 shares of the company’s stock after selling 19 shares during the period. Ignite Planners LLC’s holdings in Eli Lilly and Company were worth $1,725,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Capital Planning LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in Eli Lilly and Company in the 1st quarter valued at $6,916,000. M&G Plc bought a new stake in Eli Lilly and Company in the 1st quarter valued at $8,896,000. HighPoint Advisor Group LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $9,878,000. Finally, Leo Wealth LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $3,355,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Company Stock Performance
Shares of Eli Lilly and Company stock opened at $898.40 on Tuesday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The firm has a 50 day simple moving average of $900.13 and a 200 day simple moving average of $848.40. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53. The firm has a market cap of $853.84 billion, a P/E ratio of 132.31, a P/E/G ratio of 2.78 and a beta of 0.42.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on LLY shares. Bank of America increased their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Citigroup started coverage on Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price target on the stock. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $977.35.
Read Our Latest Research Report on LLY
Insider Transactions at Eli Lilly and Company
In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.13% of the stock is owned by corporate insiders.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
- Five stocks we like better than Eli Lilly and Company
- Top Biotech Stocks: Exploring Innovation Opportunities
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Upcoming IPO Stock Lockup Period, Explained
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- How to Calculate Stock Profit
- RPM International Thrives in Rate-Cut Driven Construction Rally
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.